Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

Niek F. Casteleijn, A. Lianne Messchendorp, Kyong T. Bae, Eiji Higashihara, Peter Kappert, Vicente Torres, Esther Meijer, Anna M. Leliveld

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients. Methods: 70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5). Results: In these patients [65.7 % male, age 41 ± 9 years, mGFR 74 ± 27 mL/min/1.73 m2 and TKV 1.92 (1.27–2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p < 0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4). Conclusions: Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalClinical and Experimental Nephrology
DOIs
StateAccepted/In press - Jun 23 2016

Fingerprint

Autosomal Dominant Polycystic Kidney
Polyuria
Vasopressin Receptors
Ureter
Kidney
Kidney Pelvis
Placebos
Urine
tolvaptan
Dilatation
Therapeutics
Growth

Keywords

  • Autosomal dominant polycystic kidney disease
  • Polyuria
  • Tolvaptan
  • Ureter

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. / Casteleijn, Niek F.; Messchendorp, A. Lianne; Bae, Kyong T.; Higashihara, Eiji; Kappert, Peter; Torres, Vicente; Meijer, Esther; Leliveld, Anna M.

In: Clinical and Experimental Nephrology, 23.06.2016, p. 1-8.

Research output: Contribution to journalArticle

Casteleijn, Niek F. ; Messchendorp, A. Lianne ; Bae, Kyong T. ; Higashihara, Eiji ; Kappert, Peter ; Torres, Vicente ; Meijer, Esther ; Leliveld, Anna M. / Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. In: Clinical and Experimental Nephrology. 2016 ; pp. 1-8.
@article{dd61e0f3ed7646e08b77ca98e2d6b8fd,
title = "Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients",
abstract = "Background: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients. Methods: 70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5). Results: In these patients [65.7 {\%} male, age 41 ± 9 years, mGFR 74 ± 27 mL/min/1.73 m2 and TKV 1.92 (1.27–2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p < 0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4). Conclusions: Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.",
keywords = "Autosomal dominant polycystic kidney disease, Polyuria, Tolvaptan, Ureter",
author = "Casteleijn, {Niek F.} and Messchendorp, {A. Lianne} and Bae, {Kyong T.} and Eiji Higashihara and Peter Kappert and Vicente Torres and Esther Meijer and Leliveld, {Anna M.}",
year = "2016",
month = "6",
day = "23",
doi = "10.1007/s10157-016-1297-1",
language = "English (US)",
pages = "1--8",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients

AU - Casteleijn, Niek F.

AU - Messchendorp, A. Lianne

AU - Bae, Kyong T.

AU - Higashihara, Eiji

AU - Kappert, Peter

AU - Torres, Vicente

AU - Meijer, Esther

AU - Leliveld, Anna M.

PY - 2016/6/23

Y1 - 2016/6/23

N2 - Background: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients. Methods: 70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5). Results: In these patients [65.7 % male, age 41 ± 9 years, mGFR 74 ± 27 mL/min/1.73 m2 and TKV 1.92 (1.27–2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p < 0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4). Conclusions: Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.

AB - Background: Tolvaptan, a vasopressin V2 receptor antagonist, has been shown to reduce the rates of growth in total kidney volume (TKV) and renal function loss in ADPKD patients, but also leads to polyuria because of its aquaretic effect. Prolonged polyuria can result in ureter dilatation with consequently renal function loss. Therefore, we aimed to investigate the effect of tolvaptan-induced polyuria on ureter diameter in ADPKD patients. Methods: 70 ADPKD patients were included (51 were randomized to tolvaptan and 19 to placebo). At baseline and after 3 years of treatment renal function was measured (mGFR) and MRI was performed to measure TKV and ureter diameter at the levels of renal pelvis and fifth lumbar vertebral body (L5). Results: In these patients [65.7 % male, age 41 ± 9 years, mGFR 74 ± 27 mL/min/1.73 m2 and TKV 1.92 (1.27–2.67) L], no differences were found between tolvaptan and placebo-treated patients in 24-h urine volume at baseline (2.5 vs. 2.5 L, p = 0.8), nor in ureter diameter at renal pelvis and L5 (4.0 vs. 4.2 mm, p = 0.4 and 3.0 vs. 3.1 mm, p = 0.3). After 3 years of treatment 24-h urine volume was higher in tolvaptan-treated patients when compared to placebo (4.7 vs. 2.3 L, p < 0.001), but no differences were found in ureter diameter between both groups (renal pelvis: 4.2 vs. 4.4 mm, p = 0.4 and L5: 3.1 vs. 3.3 mm, p = 0.4). Conclusions: Tolvaptan-induced polyuria did not lead to an increase in ureter diameter, suggesting that tolvaptan is a safe therapy from a urological point of view.

KW - Autosomal dominant polycystic kidney disease

KW - Polyuria

KW - Tolvaptan

KW - Ureter

UR - http://www.scopus.com/inward/record.url?scp=84976336966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976336966&partnerID=8YFLogxK

U2 - 10.1007/s10157-016-1297-1

DO - 10.1007/s10157-016-1297-1

M3 - Article

SP - 1

EP - 8

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

ER -